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Introduction
Reductions in physical activity and weight-bearing, such as
those associated with mechanical unloading in spaceflight or bed
rest, are known to induce considerable bone loss, characterized
by loss of bone mass and alterations in biochemical markers of
bone metabolism1-4. One important pathway in the control of
bone formation that is currently receiving ample attention is the
Wnt signaling pathway. Activation of Wnt signaling occurs upon
binding of Wnt glycoproteins to the co-receptors osteoblast
membrane-bound Frizzled receptor and low-density lipoprotein
receptor-related proteins 5 and 6 (LRP5, 6). Signals inside the
cell are generated through β-catenin, which regulates transcrip-
tion of genes that promote osteoblastic bone formation5-8. This
pathway is involved in the bone’s response to both loading and
unloading9. Osteocytes, which are usually considered to be the
“mechanosensors” in the control of bone adaptation10,11, produce
a glycoprotein called sclerostin, coded by the SOST gene, which
binds to LRP5 and 6 to prevent formation of the Frizzled/LRP
receptor complex and thus Wnt-mediated signaling12. A series of
animal studies on rats and mice have confirmed that sclerostin is
an inhibitor of bone formation, whereas sclerostin expression is
increased in response to unloading and depressed due to mechan-
ical loading13,14. Accordingly, physical activity in humans seems
to elicit decreases in sclerostin levels as demonstrated by Ardawi
et al.15 in premenopausal women.
To the best of our knowledge, only a very few studies on
sclerostin response to unloading have been conducted in hu-
mans. Gaudio et al.16 reported that postmenopausal women af-
fected by a single episode of stroke, 6 months before they were
included in the study, had higher serum levels of sclerostin
than their age-matched peers. This change was paralleled by
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Objectives: Wnt signaling pathway may be crucial in the pathogenesis of disuse-induced bone loss. Sclerostin and DKK1,
antagonists of the Wnt signaling pathway, were assessed during immobilization by bed rest in young, healthy people. Methods:
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plied to eight healthy young male test subjects in study 1 and 21 days of head-down-tilt bed rest to seven healthy male subjects
in study 2. Results: Sclerostin levels increased in both studies during bed rest (study 1, 0.64±0.05 ng/ml to 0.69±0.04 ng/ml,
P=0.014; study 2, 0.42±0.04 ng/ml to 0.47±0.04 ng/ml, P=0.008) and they declined at the end of the 14- and 21-day bed rest pe-
riods. DKK1 decreased during the bed rest period in study 1 (P<0.001) but increased during bed rest in study 2 (P=0.006). As
expected, bone formation marker PINP decreased (study 1, P=0.013; study 2, P<0.001) and bone resorption marker NTX increased
during bed rest (P<0.001). Conclusion: Data suggest that the Wnt signaling pathway is involved in disuse-induced bone loss in
young, healthy humans. 
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high bone resorption and low bone formation rates in the pa-
tient group. In a recently published study by Spatz et al.4 90
days of bed rest led to elevated sclerostin levels after 28 days
of bed rest with a peak on day 60 in young healthy subjects.
However, and in apparent contrast, sclerostin levels in patients
with spinal cord injury were found to be lower than in an am-
bulating control group17,18. 
Another inhibitor of the Wnt signaling pathway is Dick-
kopf-related protein 1 (DKK1)19. Butler et al.20 have shown
that serum DKK1 expression is highly correlated with bone
mass variables; inverse associations have been found between
serum DKK1 expression and lumbar and femur T-scores. Nev-
ertheless, immobilization-induced increases in serum DKK1
level have not been detected until recently16. It would be de-
sirable to obtain more data in a younger and healthy popula-
tion, to elucidate the physiological role of Wnt signaling in
immobilized humans. 
We hypothesized that elevations in serum sclerostin and
DKK1 levels would occur as a result of immobilization during
14 and 21 days of bed rest in healthy young men, and we were
particularly interested in the time course of the expected
changes. 
Material and Methods
The described analyses were done as part of the so called “Vi-
bration Bed Rest” (VBR) study (in the following named study
1) and the “Nutritional Countermeasures” (NUC) bed rest study
(in the following named study 2) conducted at the DLR, German
Aerospace Center in Cologne, Germany, at the Institute of Aero-
space Medicine, in 2004/5 (study 1) and 2010 (study 2).
The studies were approved by the ethics committee of the
Aerztekammer Nordrhein (North Rhine Medical Association),
Duesseldorf, Germany, and were designed and performed in com-
pliance with the Declaration of Helsinki. Studies are registered in
the German Clinical Trial Register (http://register.germanctr.de)
(study 1: DRKS00000140) or on http://www.clinicaltrials.gov
(study 2: NCT01509456). 
Study design
Subjects were immobilized for 14 days (HDT1 - HDT14) in
6° head-down-tilt bed rest in study 1 and for 21 days (HDT1 -
HDT21) in head-down-tilt bed rest in study 2. Subjects were
ambulatory during the baseline (study 1: 4 days, BDC-4 to
BDC-1; study 2: 7 days, BDC-7 to BDC-1) and recovery (study
1: 5 days, R+0 to R+4; study 2: 6 days, R+0 to R+5) data col-
lection periods. Reambulation occurred in the morning of R+0.
Both studies originally had a crossover design and aimed at
investigating different countermeasures (vibration training and
nutrition) was the primary purpose. Description of the primary
goals are or will be described elsewhere since it is not relevant
for the data given in this paper (study 121,22, study 223,24). In
both studies the control condition was bed rest only without
applying countermeasures. As only the control conditions of
both studies are scientifically comparable for the purpose of
this publication, sample analysis as described in this paper was
restricted only to the control conditions (bed rest without coun-
termeasures) for both studies. 
Subjects in a head–down-tilt bed rest study stay in bed for
24 hours per day with the main body axis inclined by -6°, that
is, with the head below the level of the feet. All leisure activ-
ities and hygienic procedures were performed in this position.
It has to be mentioned that test subjects in study 1walked twice
a day 25 steps from their sleeping room to a training room in
which the training of the intervention group was performed. 
While they were in bed, volunteers were not allowed to raise
their heads >30° from normal or to perform dynamic or static
muscle contractions. Subjects were instructed to turn over in bed
mainly by moving their arms. Compliance with the protocol was
ascertained by supervised nursing staff and video control. 
Subjects
Respectively eight (study 1) and seven (study 2) healthy
young male test subjects (study 1: age, 26.4±4.9 years; body
mass, 78.1±9.5 kg; study 2: age, 27.6±3.3 years; body mass,
78.6±6.4 kg) took part in the studies after they had given writ-
ten informed consent. For both studies, candidates had been
excluded if they had chronic hypertension, diabetes, obesity,
arthritis, hyperlipidemia, any hepatic disease, or a disorder of
calcium or bone metabolism. All volunteers were nonsmokers,
were not taking any medication, and were exercising less often
than four times a week before study onset. Moreover, heritable
blood clotting disorders (AT III, S-Akt, Lupus-PTT, ferritin,
Factor V Leiden, Factor IV, and Factor II) were screened for
in study 2, and candidates were excluded if they had positive
test results. A psychological examination to ensure reliability
of test subjects was part of the inclusion process as well. 
Diet
The diet in both studies was constant and controlled for macro-
and micronutrients matching the dietary reference intakes25.
All ingredients, food items, and beverages for each test subject
were weighed on a laboratory scale with a precision of 0.1 g. To
confirm standardized nutrient intake, test subjects were encour-
aged to eat and drink only and to the full extent the meals pro-
vided to them, and their compliance was checked by the facility
supervisor. 
Sample collection
Fasting blood samples were taken in the supine position
under standardized conditions at 7:00 a.m. shortly after sub-
jects awakened and before they had breakfast. Blood was
drawn on days BDC-1; HDT2, 6, 8, 11, and 14; and R+2, and
+4 in study 1 and on BDC-2; HDT2, 6, 10, 14, and 21; and
R+2 and +5 in study 2. Whole blood was centrifuged (3000
rpm, 4°C, 10 minutes) after coagulation, and serum was dis-
tributed in small aliquots and immediately frozen at -80°C
until analysis.
Urine was collected as 24-h urine pools on all study days.
The first morning sample was scheduled each day at 7:00 a.m.
Each void was kept dark and cold until final pooling in the 24-
h urine pool. Aliquots were stored at -20°C. 
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All samples for analysis from study 2 were analyzed after a
storage period at -80°C of nearly 1 year. Samples from study
1 for the analysis of PINP and NTX were analyzed after a stor-
age period of 1.5 years. Samples from study 1 were stored for
nearly 8 years at -80°C before they were analyzed for scle-
rostin and DKK1.
Laboratory methods
Serum concentrations of sclerostin, DKK1, PTH (only meas-
ured in study 2, bone resorption marker urinary NTX) and bone
formation marker N-terminal propeptide type I (PINP) were de-
termined with commercially available assays in the in-house
laboratory of the Institute of Aerospace Medicine, Germany. 
Sclerostin and DKK1 were measured by enzyme-linked im-
munosorbent assays (ELISA) (sclerostin, TECO®; DKK1; both
TECOmedical GmbH Bünde, Germany). 
Interassay variation was as follows: study 1: sclerostin,
3.4%; DKK1, 3.0%; study 2: sclerostin, 0.75%; DKK1, 2.7%.
Intraassay variation was as follows: study 1: sclerostin, 4.5%;
DKK1, 1.7%; study 2: sclerostin, 1.4%; DKK1, 2.3%. Intra-
and interassay variation based on the following concentrations:
Sclerostin: 0.42-0.69 ng/ml, DKK1: 5.5-10.3 pmol/l. The bone
formation marker PINP was analyzed by a radioimmunoassay
(Orion Diagnostica, Finland), the bone resorption marker NTX
was analyzed by ELISA (Osteomark®, TECOmedical GmbH,
Bünde, Germany) and parathyroid hormone (PTH) was deter-
mined with kits from Immunotech, Beckmann Coulter GmbH,
Krefeld, Germany. Interassay variation was as follows: study
1: PINP, 2.2%; NTX, 5.8%; study 2: PINP, 3.8%, NTX, 4.9%,
PTH, 7.9% Intraassay variation was as follows: study 1: PINP,
2.2%; NTX, 5.0%; study 2: PINP, 1.9%, NTX, 1.3%. Intra- and
inter assay variation based on the following concentrations:
PINP: 35.7-53.8; 86-177 μg/l, NTX: 334-566; 1010-1689
nmol/l, PTH: 65-98; 234-352 pg/ml.
Serum and urinary calcium concentrations were analyzed
in duplicate by flame photometry (EFOX 5053, Eppendorf,
Germany).
Statistical analysis
Subjects’ age and weight data are presented as means ± SD,
and all other data are given as means ± SEM.
Linear mixed-effect models were constructed, with time as
a fixed factor and subject as a random factor, as described in 26.
Models were checked for heteroskedacity and with quantile-
quantile plots. Where necessary Box-Cox transformation was
performed before P-values were derived. These computations
were done with the R statistical environment (www.r-
project.org) in its version 2.13.1 (dated 2011-07-08).
Comparison of serum calcium, urinary calcium and PTH
levels between baseline and the mean of the intervention levels
values was done with Student’s t-test for dependent variables.
An alpha level of 0.05 was set for all tests to indicate sig-
nificance.
Results
Sclerostin
In study 1 sclerostin levels increased from 0.64±0.05 ng/ml
to maximum values of 0.69±0.04 ng/ml on HDT11 (P=0.014).
Sclerostin levels were back to baseline on HDT14, that is, on
the last day of the bed rest period (Figure 1), and they were
again increased during the recovery period (P=0.012).
In study 2, sclerostin levels showed a steady increase, start-
ing from 0.42±0.04 ng/ml (before bed rest) and reaching max-
Figure 1. Serum sclerostin levels in the time course of study 1 (left) and study 2 (right). Shown are mean values ± SEM. Sclerostin levels in-
creased in both studies during bed rest and declined at the end of the bed rest period. P-values refer to change from baseline. *P<0.05, **P<0.01
(Linear mixed-effect models).
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imum values of 0.47±0.04 ng/ml on HDT14 (P=0.008). As in
study 1, sclerostin levels decreased on the last day of the bed
rest phase (HDT21), when they were approaching baseline lev-
els. However, unlike in study 1, sclerostin levels did not in-
crease again, but rather showed a further decrease in the
recovery period, and baseline levels were reached on R+5
(0.42±0.04 ng/ml) (Figure 1).
DKK1
In study 1, DKK1 levels decreased from a high baseline
level (42.3±6.1 pmol/l) to a minimum level of 36.0±4.4 pmol/l
(P<0.001) during bed rest, decreasing further until day R+2 in
the recovery period (34.7±4.5 pmol/l) (P<0.001) (Figure 2). 
In study 2, conversely, DKK1 levels were increased over
baseline levels (33.4±2.6 pmol/l vs. 37.9±2.5 pmol/l) as early
as HDT2 (P=0.006). During bed rest, DKK1 levels remained
constantly elevated, and they returned to baseline levels of
32.0±1.7 pmol/l within 3 days after bed rest ended (Figure 2).
Bone formation and resorption 
Part of the results, but focusing on the primary study inten-
tion, are presented by our working group elsewhere22. In study
1 a significant decrease in the bone formation marker PINP
could be detected on HDT 11 (P=0.013) (Figure 3). The urinary
bone resorption marker NTX was increased on the third day of
bed rest compared to the mean of the baseline levels, and in-
creased further over time during bed rest (P<0.001) (Figure 4).
In study 2, PINP was reduced during bed rest (P<0.001)
Figure 2. Serum DKK1 levels in the time course of study 1 (left) and study 2 (right). Shown are mean values ± SEM. DKK1 decreased during
bed rest in the study 1. DKK1 was elevated during bed rest in study 2. P-values refer to change from baseline. *P<0.05, **P<0.01, ***P<0.001
(Linear mixed-effect models).
Figure 3. Changes in serum PINP levels from baseline of the different time points of study 1 (left) and study 2 (right). Shown are mean values
± SEM. The bone formation marker PINP decreased during the 21-day study, whereas a significant decrease in the 14-day bed rest study was
detected only on day 11 of HDT. P-values refer to change from baseline. *P<0.05, **P<0.01, ***P<0.001 (Linear mixed-effect models).
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from a baseline level of 70.8±7.3 μg/l to a minimum value on
HDT21 of 58.1±5.2 (P<0.001). PINP levels did not reach base-
line levels during the recovery period (Figure 3). NTX was al-
ready increased in the first days of bed rest (P<0.001) and
showed further increases in the course of the bed rest period
(P<0.001) (Figure 4). 
Calcium and PTH
In both studies serum calcium levels were unchanged and
urinary calcium increased during bed rest (P<0.001) as ex-
pected. Study 2 exposed a reduction in PTH during 21 days of
immobilisation (P<0.001) (Table 1).
Discussion
In the present study we assessed alterations in serum levels
of sclerostin and DKK1 in response to bed rest-induced im-
mobilization in young male human volunteers. Data from both
studies provide clear evidence that sclerostin is elevated during
bed rest. In addition to the 90 days bed rest study of Spatz et
al.4, with the first sclerostin measurement on bed rest day 28,
these data show that sclerostin is already elevated after eight
(study 1) to eleven (study 2) days of disuse. Sclerostin levels
seemed to decline toward the end of the bed rest period. The
results of the studies are discordant with regard to DKK1 lev-
els. Well-known markers of bone resorption (urinary NTX),
bone formation (PINP), serum and urinary calcium and PTH
changed as expected in the course of immobilization. In con-
clusion, the data suggest that sclerostin and Wnt signaling in
general are involved in disuse-induced bone loss in young,
healthy adult humans. 
In both studies we found an unexpected decline in serum
sclerostin at the end of the bed rest period on the last day be-
fore subjects became ambulatory again. Also Spatz et al.4 ded-
icated a lesser increase of sclerostin on day 90, which was the
last bed rest day in this study. This is unlikely to reflect a spe-
cific temporal pattern of the sclerostin response, because the
studies had different durations. Rather, could it be the antici-
pation of reambulation that leads to the decline at the end of
the bed rest period through brain-bone interactions? This may
sound like a remote possibility, but some neural mediators,
such as leptin and serotonin that may link the brain to the
skeleton have already been identified27. Experiments on mice
demonstrated that sympathetic tone regulates bone mass,
mainly by influencing osteoblasts. Additional brain-bone in-
teractions are suggested by results from studies in rats of the
effects of β-blockers, very low doses of which are able to in-
crease bone formation markers28. In further support of the ex-
istence of this mechanism of bone regulation, in humans it is
known that children taking sympathomimetics to treat asthma
have a low bone mass29. As sclerostin interacts with multiple
neurotransmitter and other proteins that alter bone formation
and resorption, and is likely to function by altering several bi-
Figure 4. Changes in urinary NTX levels from the mean of the baseline values of the different time points of study 1 (left) and study 2 (right).
Shown are mean values ± SEM. In both studies, the bone resorption marker NTX started to increase in the first days of bed rest and showed
further increases later in the bed rest period. P-values refer to change from baseline. P<0.001 (Linear mixed-effect models). 
Table 1. Serum calcium, urinary calcium and PTH at baseline and
during bed rest. Shown are mean values ± SEM.
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ologically relevant pathways in bone, a brain-bone interaction
could be considered.
In general, the exact mechanism of sclerostin stimulation
and action is not completely understood. There is no doubt that
osteocyte sclerostin production is regulated substantially by
the mechanical environment of bone, and it seems as if load-
ing-induced down regulation would be an early osteogenic re-
sponse to strain rather than a consequence of strain itself30.
Regarding DKK1, to the best of our knowledge this is the
first study showing that immobilization leads not only to in-
creased sclerostin, but also to increased DKK1 levels after the
onset of bed rest. This was observed as early as bed rest day 2
in study 2. However, study 1 showed an opposite reaction of
DKK1 levels. Due to the long storage period of samples from
study 1 for DKK1 analysis, considering a possible effect on
the quality of samples, we would argue that findings from
study 2 give a more realistic picture of DKK1 levels, and we
conclude that a clear role exists for DKK1 in the mediation of
bone formation in response to unloading in humans. We should
not neglect to mention that study 1 test subjects´ short walk
twice a day during the bed rest period could have had an im-
pact on DKK1 levels as well. Moreover, subjects of study 1
started with an unexplainable high baseline level. 
Serum levels of DKK1 reacted even faster to unloading than
sclerostin levels did. One possible reason is that DKK1 could
have a higher affinity for the receptor LRP5/6, and the binding
of DKK1 to LRP5/6 triggers osteocytes to increase the expres-
sion of DKK1 first. Balemans et al.31 demonstrated that DKK1
and sclerostin do not simultaneously bind to wild-type LRP5,
and that DKK1 is able to displace sclerostin from previously
formed sclerostin-LRP5 complexes. They conclude that DKK1
and sclerostin are independent, and not synergistic, regulators
of LRP5.
Knowledge of sclerostin’s actions led rather quickly to the
development of sclerostin antibodies in both animals and hu-
mans to be used primarily as an anabolic therapeutic agent in
the treatment of osteoporosis32-34. But, because of the described
sclerostin changes in immobilization, anti-sclerostin antibodies
seem to also show promise as a new countermeasure to limit
bone loss during immobilized conditions, or when astronauts
are in space. A host of preclinical animal studies have shown
salutary effects on bone formation in animal models such as
ovariectomized rats and aging animals. A human antisclerostin
antibody, known as AMG 785, developed by Amgen (Thou-
sands Oaks, CA) and UCB Inc. (Smyrna, GA), was associated
with an increase in bone formation as well as a decrease in bone
resorption, which supports the recent in vitro evidence for scle-
rostin’s additional catabolic activity. Also, lumbar spine and
total hip bone mineral density increased 5.3% and 2.8%, re-
spectively, in a dose-dependent manner 3 months after admin-
istration of AMG 78535. Clinical studies performed in healthy
humans showed that serum sclerostin levels increase markedly
with age36,37, which makes sclerostin even more important as a
target of therapeutic agents against bone loss in the elderly. 
The results of our study suggest a therapeutic potential for
DKK1 antibodies as well. Some preclinical studies in mice and
monkeys have shown promising effects of anti-DKK1 antibodies
on bone mineral density38-41. Anti-DKK1 therapies in humans are
limited to studies with multiple myeloma patients, as osteolytic
lesions and fractures, which have positive correlations with serum
DKK1 level42-44, are potential complications in these patients. 
Due to only small group of subjects in our studies, more
studies are needed to get insight into the activation of sclerostin
and DKK1 and their effects on the processes of bone formation
and bone resorption as well as on possible interactions between
sclerostin and neuronal factors as mediators that connect the
brain to the skeleton. 
In conclusion, the described data from two bed rest studies
show strong evidence for alterations in Wnt signaling during
experimental bed rest in young, healthy male human test sub-
jects occurring already after just a bit more than a week and
highlight especially the key roles of sclerostin and DKK1 in
the regulation of bone metabolism. 
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